睿知中国医院研究地图
候选清单

正在招募鼻咽癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06976190,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with histologically and cytologically confirmed recurrent or metastatic nasopharyngeal carcinoma (NPC) who have failed at least one line of prior systemic therapy.

    入选标准第 3 条

  3. Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.

    入选标准第 8 条

    Received systemic chemotherapy, targeted therapy, biological therapy or immunotherapy for anti-tumor purpose, or major surgery within 3 weeks prior to the first dose of study treatment.

    排除标准第 2 条

    Received anti-infection therapy within 2 weeks prior to the randomization

    排除标准第 3 条

    ≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment

    排除标准第 9 条

  4. The score of ECOG for performance status is 0 or 1.

    入选标准第 5 条

  5. Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

    入选标准第 4 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06976190,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Willing to sign the informed consent form and follow the requirements specified in the protocol.
  2. Life expectancy ≥ 12 weeks.
  3. Patients with histologically and cytologically confirmed recurrent or metastatic nasopharyngeal carcinoma (NPC) who have failed at least one line of prior systemic therapy.
  4. Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
  5. The score of ECOG for performance status is 0 or 1.
  6. No severe cardiac dysfunction, left ventricular ejection fraction (LVEF) ≥50%.
  7. Organ functions and coagulation function must meet the basic requirements.
  8. Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.

排除标准:Exclusion Criteria:

  1. History of hypersensitivity to any component of the investigational product.
  2. Received systemic chemotherapy, targeted therapy, biological therapy or immunotherapy for anti-tumor purpose, or major surgery within 3 weeks prior to the first dose of study treatment.
  3. Received anti-infection therapy within 2 weeks prior to the randomization
  4. Prior treatment with MMAE/MMAF ADC drugs
  5. Central nervous system metastasis.
  6. Poorly controlled systemic diseases
  7. Patients with poorly controlled heart diseases
  8. Poorly controlled pleural and peritoneal effusion or pericardial effusion
  9. ≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment
  10. Patients with prior ≥Grade 3 immuno-related adverse events (irAEs)
  11. Any clinically significant arteriovenous bleeding, pulmonary embolism, or deep venous thrombosis occurred within 3 months
  12. Received allogeneic tissue/solid organ transplantation.
  13. Inoculate live vaccine within 30 days before the first dose.
  14. Patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate contraceptive measures during the treatment and for 180 days after the last dose of study treatment.
  15. History of other primary malignant tumor diseases.
  16. Other situations that are not suitable to participate a clinical trial per investigator's judgement

引自 ClinicalTrials.gov, NCT06976190, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06976190,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06976190